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Abstract. Background/Aim: Epithelial skin cancer
frequently occurs in the elderly population, sometimes in an
advanced stage, when intensive treatments are needed.
Radiotherapy can achieve high response rates. We evaluated
efficacy and tolerability of hypofractionated radiotherapy in
a population of very elderly patients with locally advanced
epithelial skin cancer. Patients and Methods: Two different
hypofractionated schedules were administered (21 patients):
6 Gy in 10 bi-weekly fractions (13 lesions) and 5 Gy in 12
bi-weekly fractions (13 lesions). Median age at treatment was
88 years, life expectancy was ≤5 years in 90.5%. Results: The
overall response rate was 96.1%, with 92.4% complete
responses. All patients experienced an improvement of their
symptoms and a reduction of pain and medication. The
median overall survival time was 28 months (95% confidence
interval=4.7-51.2 months). At the time of analysis, 52.3% of
patients had died. Conclusion: Hypofractionated
radiotherapy is an effective option of treatment, with low
toxicity and optimal results, and can also be safely
administered to these frail patients.
Epithelial skin cancer is a common neoplasm. The median
patient age at diagnosis is 74 years. Its incidence is rapidly
increasing probably due to the greater sun exposure of the
population. The majority of the tumors are basal cell
carcinomas (BCC), the remainder are squamous cell
carcinomas (SCC) (1). Epithelial skin cancer is locally
aggressive and the prognosis depends on stage and histology.
Advanced stage and poor histology, such as SCC, adenoid or
adenosquamous carcinomas correlates with a higher
likelihood of metastasis and poor prognosis. Nevertheless
primary definitive treatment for localized tumors can be
curative (2). Treatment options include surgery, radiotherapy,
cryoablation, cauterization, photodynamic therapy and
topical treatment with 5-fluoruracil or imiquimod cream.
Surgery and radiotherapy (RT) are considered the most
effective treatment options (3). RT with standard
fractionation can achieve a high rate of local control (4-9).
Although screening has increased the identification of
precancerous lesions, in some cases, skin cancer is still
frequently diagnosed in an advanced stage and in elderly
people; at this stage, intensive and sometimes disfiguring
treatments are needed. Invasive or time-consuming
interventions (such as conventional RT) sometimes cannot
be performed or completed in elderly patients due to
comorbidities, cognitive impairment, poor living conditions
or the absence of a continuity of care.
RT is a curative treatment option for elderly patients or
when patients are not eligible for or decline surgery; RT can
also be performed in the adjuvant setting or in the case of
incomplete surgical excision, when re-excision is not
possible.
The standard RT regimen consists of daily sessions (5
days per week) for 4-6 weeks. Many elderly patients may
have difficulties in making multiple hospital visits due to
difficulties in mobilizing, comorbidities, cognitive
impairment or logistical impediments. A hypofractionated
regimen, where the number of fractions and the sessions per
week are reduced but the dose per fraction is increased, can
be more suitable for this kind of patient; moreover, some
evidence suggests that a dose per fraction of more than 3 Gy
can actually result in better local control (7-10).
We evaluated the efficacy and tolerability of
hypofractionated RT in a population of very elderly patients
with locally advanced-stage epithelial skin cancer. Because
local treatment can be curative, our primary endpoints were
local control (LC) and compliance with treatment. Secondary
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end-points were the socio-economic impact (in terms of
reduction of the number of RT sessions and tumor
medications, hospital visitation and nurse assistance), overall
survival (OS), cancer-specific survival (CSS) and toxicity.
Patients and Methods
Patient and disease characteristics. From June 2011 to September
2015, we treated 26 epithelial skin cancers in 21 very elderly
patients. Patients were eligible for the treatment if they had three or
more of the following inclusion criteria: age >80 years, unresectable
epithelial skin cancer, surgery with positive margin non-eligible for
re-excision, severe comorbidities and cognitive impairment. 
Nine (43%) patients were male and 12 (57%) were female.
Median age at the treatment was 88 years (range=77-100 years), 13
(62%) patients had an Eastern Cooperative Oncology Group
Performance Status (ECOG PS) of 1-2 and eight (38%) patients had
a PS of 3-4. Patient characteristics are reported in Table I.
Tumor characteristics are summarized in Table II. The most
common histology was SCC, [14 lesions (54%)]. Nineteen (73%)
tumors were unresectable because of advanced stage or patient
comorbidity, six (23%) had positive margins (micro- or macroscopic
infiltration) after surgery, and one (4%) had macroscopic local
relapse 6 months after radical surgery. 
Twenty-one (80.8%) tumors were localized in the head, four
(15.4%) in the limbs and one in the chest (3.8%), as detailed in
Table III.
The current study was carried out in accordance with the
Declaration of Helsinki (1964) and the Internal Review Board
approved the study. Written inform consent was obtained from
patients or their legal representatives.
Treatment. Patients were treated using electron beam or photons
depending on tumor site, dimensions and depth. Electron beam
energy (range=6-12 MeV) was chosen on the basis of the estimated
tumor depth. The target volume consisted of the tumor area plus a
margin of 1-2 cm to include microscopic extension. The skin-
sparing effect of the electron beam therapy was compensated, where
necessary, by bolus to the target area. Patients treated with photons
underwent pre-treatment computed tomography. The gross tumor
volume (GTV) was defined as the entire tumor mass; the clinical
target volume (CTV) was obtained by adding a 1 cm margin in all
directions to include the microscopic extension. A margin of 1 cm
in all directions was added to the CTV to generate the planning
target volume (PTV). RT was delivered with a Varian Linear
Accelerator using 6-MV photon beam.
At the beginning of the study, five lesions (19.2%) were treated
with a one fraction per week schedule with incremental dose per
fraction from 5 Gy for 12 fractions (three patients) to 6 Gy for 10
fractions (two patients) [biological equivalent dose (BED)
range=90-96 Gy with α/β=10 for early responding tissues].
These fractionations were chosen to give a higher BED with
respect to the 66 Gy delivered in 30 fractions of 2.2 Gy (BED
80.5 Gy) used in compliant patients at our Institution, also
considering a longer total treatment time (10-12 weeks vs. 6
weeks). Subsequently, considering the good compliance of treated
patients and with the aim of reducing the total treatment time, we
increased the number of fractions to two per week. Two different
hypofractionated schedules were administered: the first 10 cases
(38.5%) were treated with 12 fractions of 5 Gy and the second 11
cases (42.3%) with 10 fractions of 6 Gy. 
We used linear-quadratic (LQ) modeling in order to equate these
hypofractionation schedules to the normalized total dose (NTD) if
delivered in 2-Gy fractions (12). Thus, NTD represents the dose
given in 2-Gy fractions that would have an equivalent biologic
effect as the new hypofractionated dose:
NTD =[Dnew×(1+dnew/α/β)]/(1+2/α/β)
where Dnew and dnew were the total dose and dose per fraction for
a suggested hypofractionation scheme, respectively. The total dose
of 60 Gy given in 12 or 10 fractions, yielded NTD3 of 96 and 108
Gy (α/β=3 Gy for late toxicity) and NTD10 of 75 and 80 Gy
(α/β=10 Gy for acute toxicity), respectively. The NTD for each
schedule and treatment details are reported in Table IV.
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Table I. Patient’s characteristics (n=21).
Characteristic                                                               Value
Mean age (range) pre-RT, years                             88 (77-100)
Mean age (range) at diagnosis, years                     84 (66-95)
Gender, n (%) 
   Male                                                                        9 (43)
   Female                                                                 12 (57)
ECOG PS, n (%)
   1                                                                              4 (19)
   2                                                                              9 (43)
   3                                                                              5 (24)
   4                                                                              3 (14)
Life expectancy, n (%)
   >5 Years                                                                  2 (9.5)
   <5 Years                                                                19 (90.5)
Comorbidities (per type), n (%)
   Cardiovascular                                                      12 (57)
   Cerebrovascular                                                      7 (33)
   Metabolic                                                                5 (24)
   Osteoarticolar                                                         4 (19)
   Oncological                                                            4 (19)
   Pulmonary                                                              2 (9.5)
Comorbidities (per patient), n (%)
   0-1                                                                           9 (43)
   2                                                                              6 (28.5)
   ≥3                                                                            6 (28.5)
Charlson Age-Comorbidity Index (range)                8 (6-12)
Relative risk of death (95% CI)                               19.37 (6.38-19.37)
Mobilization
   Autonomous                                                           8 (38)
   Not-autonomous                                                     5 (24)
Use of device                                                                
   Feeding                                                                   8 (38)
   Oral                                                                       19 (90.5)
   Parenteral                                                                2 (9.5)
Home status
   Living at home                                                     16 (76)
   Hospice/retirement home                                       5 (24)
CI: Confidence interval; ECOG PS: Eastern Cooperative Oncology
Group Performance status; RT: radiotherapy.
Follow-up. Acute and late toxicity were graded according to the
European Organisation for Research and Treatment of
Cancer/Radiation Therapy Oncology Group criteria (13). Clinical
evaluation was performed weekly during the course of RT, 1 month
after the end of RT and thereafter every 3 months for 2 years. Each
visitation included evaluation by the radiation oncologist and the
dermatologist. 
Statistical method. The analysis of the tumor response and LC was
made per tumor, because a single patient could have multiple
tumors. LC, OS and CSS were calculated from the end of the RT.
OS was defined as the time from the end of RT to the last follow-
up or death. 
Kaplan–Meier method was used for calculating OS and CSS and
factors that affect LC, and a Chi-square test was used in the
univariate analyses. Data were prospectively collected, according to
our internal protocol, and a retrospective statistical analysis was
conducted using SPSS 16.0 software (SPSS Inc,, Chicago, IL, USA).
Results
Response to treatment, local and distant recurrence. Overall,
the response rate was 96.1% (25/26 lesions), of these 24
(92.4%) had a complete response and one (3.8%) a partial
response. One case (3.8%) was suspicious for progression but
biopsy could not be performed because the patient died of
kidney failure 5 months after RT completion, therefore we
considered this case as a progression. Two (9.5%) patients had
distant progression: the first patient had an SCC of the leg with
locoregional nodal involvement at diagnosis and developed
distant metastases 2 months after the end of the RT; the other
one had an advanced SCC of the scalp and developed a
metastasis in a single locoregional node 13 months after RT.
Toxicity, compliance with treatment and quality of life.
Sixteen (61.5%) cases developed acute toxicity, 12 (46.2%)
of these had grade 1-2 toxicity and four (15.3%) grade 3.
Late toxicity, represented by necrosis, occurred in three
(11.5%) cases, but none needed surgical intervention.
Compliance of patients was good; only three (11.5%)
treatments were interrupted and two (7.6%) of these were
afterwards not completed due to severe toxicity: the first case
had grade 3 mucositis and dysphagia, interrupting the
treatment at the seventh fraction (total dose=42 Gy) and died
4 months later due to myocardial infarction. The second
patient was treated for a tumor of the nose and treatment was
interrupted for 2 months due to infectious pneumonitis; after
resumption, the therapy was definitively ended at the ninth
of 10 fractions due to severe pain and conjunctivitis.
Cosmetic assessment was not performed.
All patients experienced an improvement of their
symptoms, with a reduction of pain. All patients with stage
III/IV lesions and 61.1% (11 patients) of patients with stage
II tumors received daily, sometimes multiple, medications
since before RT, in most cases administered by a private
nurse at home, the cost of which was borne by the family, in
some other cases medications were given by family members
trained to do so. We observed a reduction in the number of
medications during the course of RT proportional to the
improvement of the lesion. At the first follow-up, 23 (88.4%)
lesions had completely disappeared and no medications were
needed, only the three patients with necrosis required further
medication, but no surgical intervention.
Survival and treatment of recurrence. Median follow-up was
7 months (range=4-40 months). The median OS in our series
was 28 months (95% confidence interval=4.7-51.2). Six-
month survival was 63.8%, 1- and 2-year OS were both
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Table II. Tumor characteristics (n=26). 
Characteristic                                              No. of tumors (%)
Histology
    SCC                                                                14 (54)
    BCC                                                                  6 (23)
    Basal/squamous                                               2 (7.5)
    Other                                                                 3 (11.5)
    Unknown                                                          1 (4)
Stage
    I                                                                         1 (4)
    II                                                                     17 (65)
    III                                                                      2 (8)
    IV                                                                      6 (23)
Previous surgery
    Yes                                                                    7 (27)
    No                                                                   19 (73)
Relapse after R0 surgery
    R Status                                                            1 (4)
    R1                                                                     2 (8)
    R+                                                                     4 (15.5)
SCC: Squamous cell carcinoma; BCC: basal cell carcinoma; R0:
negative surgical margins; R1: microscopical tumor infiltration; R+:
macroscopical tumor infiltration.
Table III. Tumor localization (n=26).
Location                                                                n (%)
Cheek                                                                   6 (23)
Scalp                                                                     4 (15.3)
Nose                                                                     3 (11.6)
Temple                                                                 3 (11.6)
Inferior limb                                                        3 (11.6)
Forehead                                                              2 (7.6)
Ear                                                                        2 (7.6)
Superior limb                                                       1 (3.9)
Trunk                                                                    1 (3.9)
Eyelid                                                                   1 (3.9)
51.2%. At the time of analysis, 11/21 (52.3%) patients had
dead: one (4.7%) due to systemic spread that occurred 2
months after RT completion, one (4.7%) with suspicion of
local progression died of kidney failure 5 months after
treatment; the other nine (42.7%) patients died from causes
not related to the tumor. Ten patients (47.6%) were alive at
the time of analysis: one (4.7%) out of these patients had
developed a metastasis in a locoregional node and received
an RT course of 6 Gy in 10 fractions twice per week.
The median CSS was not reached. One and 2-year CSS
were both 95%.
Univariate analysis. No differences were seen in response to
treatment by histological type (SCC vs. non-SCC; p=1.);
nevertheless, it should be noted that the only partial response
and the suspected case of progression both occurred in the
SCC group. Distant recurrence occurred in two (9.5%)
patients, both in the SCC group, but correlations with response
and with fractionation were not statistically significant.
No differences were seen in response to treatment according
to factors such as sex, age, life expectancy, pre-treatment PS,
localization of tumor, staging, prior surgery and treatment
interruption. Moreover, the two different fractionations (5
Gy/12 fr and 6 Gy/10 fr) and the administration schedule
(mono- or biweekly) did not significantly correlate with
response, histology or toxicity.
Discussion
RT is a mainstay in the treatment of epithelial skin cancer
and is the most effective option for patients not suitable for
surgery. LC rates after RT with standard fractionation for
primary BCC and SCC have been reported to be 87-98% and
56-97%, respectively (4-8). Some evidence showed that
hypofractionated schedules could achieve a high rate of LC
(10). Elderly patients may not be able to attend hospital daily
because of comorbidities or poor socio-economic conditions,
therefore they can benefit from a reduction of the number of
fractions. The rationale of the present study comes from the
need to administer a safe and effective treatment to patients
that are unable to comply with daily treatment, such as
elderly ones, patients with comorbidities or cognitive
impairment, and to reduce the cost of treatments. 
The primary end-points were LC and compliance with
treatment; secondary end-points were the socio-economic
impact (in terms of reduction of the number of RT sessions
and tumor medications, hospital visitation andnurse
assistance), OS, CSS and toxicity. The altered fractionation
well suited this objective.
The first evidence on the efficacy of hypofractionation for
these tumor types comes from a study of Locke et al. (10);
the study showed that the rate of LC for BCC of 1.1-5 cm
was higher when the dose per fraction increased from <2 to
3.01 to 4 Gy (75%, 95% and 100% respectively; p=0.01).
Moreover, patients receiving a total dose >60 Gy had
significantly lower LC when a fraction size <2 Gy was used
compared with a larger fraction size (p=0.01). An
improvement in local control was also seen for SCC when
the dose per fraction increased (73% for <2 Gy to 100% for
>4 Gy in ≤1 cm lesions), even if the association was not
statically correlated. 
In a study of van Hezewijk et al. the Authors administered
two hypofractionation schedules (54 Gy in 18 fractions of 
3 Gy or 44 Gy in 10 fractions of 4.4 Gy). The increased dose
per fraction resulted in a higher local recurrence-free rate,
increasing from 96.1% in the 54 Gy schedule to 97.5% in
the 44 Gy schedule (9). Nevertheless the rate of T1-2 lesions,
which are known to be the best responders to local treatment,
was quite high (86.8%) compared with our series.
LC in the present study was 96.1% (25 out of 26 treated
lesions), with only ase suspicious for progression; the
complete rate was 92.4% (24 out of 26 treated lesions). The
rate of stage III or IV tumors (31%) of our study population
was high in comparison with other studies on curative
hypofractionation (9, 10) or adjuvant hypofractionation (15).
From the analysis of the literature available to date, some
consideration about the total dose of the treatment should be
made. As previously reported (8), the association of
increasing BED with improved LC supports a radiation
dose–response relationship. 
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Table IV. Treatment characteristics (n=26).
Total dose                       Dose/fr            No. of fractions                   Schedule                       NTD3Gy*                   NTD10Gy**                      BED10Gy
60 Gy (n=3)                     5 Gy                         12                          Mono-weekly                      96 Gy                          75 Gy                              90 Gy
60 Gy (n=2)                     6 Gy                         10                          Mono-weekly                     108 Gy                         80 Gy                              96 Gy
60 Gy (n=10)                   5 Gy                         12                             Bi-weekly                         96 Gy                          75 Gy                              90 Gy
60 Gy (n=11)                   6 Gy                         10                             Bi-weekly                        108 Gy                         80 Gy                              96 Gy
NTD: Normalized total dose; *calculated with an α/β=3 Gy for low-proliferating tumors and for late toxicity; **calculated with an α/β=10 Gy for
early-responding tissues; BED: biological equivalent dose calculated with an α/β=10 Gy for early-responding tissues.
Khan et al. administered two regimens of 40 Gy in 10
fractions and 50 Gy in 20 fractions (BED range=56-62.5
with α/β=10; NTD range = 46.7-52.1 Gy with α/β=10);
they reported an LC rate of 84.2% (14), which is lower than
those of other studies, concluding that an NTD higher than
56 Gy is recommended, especially for lesions greater than
2 cm. The higher BED reported in the study of van
Hezewijk et al. (9) (range=63.4-70.2 Gy, with α/β=10)
resulted in higher LC (96.1-97.5%), with a crude rate of
recurrence of 3.4%; nevertheless considering lesions per
stage, the rate of recurrence for T3 tumors was significantly
higher (18.1%, 2/11 lesions) and both events occurred in the
44 Gy group. The BED of our treatments was higher than
the that reported in the literature (BED range=90-96 Gy),
with only one case (4.7%) suspicious for local progression
and two cases (9.5%) out of 21 patients with distant
metastases. Both distant recurrences occurred in patients
with very advanced SCC: the first had nodal involvement at
the time of local treatment and died of metastatic spread a
few months after the end of the therapy, probably reflecting
an early dissemination of the disease; the second had a T4
tumor of the ear and developed a single metastasis in a
locoregional node that has been treated with a 6 Gy×10 bi-
weekly RT. After a median OS of 28 months, we reported
no cases of local recurrence, but only one suspicious of
progression; this result, even if retrospective, is remarkable,
considering that the median time to local relapse for SCC is
3.3-5 months and for BCC is 10.4-40.5 months (4,9,16).
With regard to histology, it is known that SCC is locally
and distantly aggressive. We reported one case suspicious for
local progression and two cases of distant progression
occurring in patients affected by SCC, but the correlation
with the treatment schedule was not statistically significant.
This result probably derived from the low rate of events in
our series, therefore by increasing the series size, it should
be possible to observe a significant difference.
The population included in the present study consisted of
a homogeneous series of elderly patients with advanced-
stage skin tumors who were unable to undergo surgery, nor
daily RT, in most cases they also had comorbidities or
cognitive impairment. For these patients, the reduction of the
number of fraction resulted in a higher adherence to
treatment; we reported only three (11.5%) cases of
interruption, but only in one case was the reason due to
unacceptable toxicity and the treatment was then not
completed. The toxicity rate reported in our series suggests
the safety of the proposed schedules.
Limitations of our study are the low sample size and its
retrospective nature which does not allow us to compare the
relative effectiveness of the proposed treatments, even
considering the low rate of recurrence. Prospective studies
are needed to confirm these data and to evaluate efficacy
also in the general population.
Conclusion
Hypofractionated RT is an effective treatment option and can
be safely administered in elderly patients, with low toxicity
and optimal results. The toxicity is acceptable and the rate
of withdrawal is low. Considering the high rate of LC
achieved with both schedules, we suggest the use of the
schedule of 6 Gy in 10 (biweekly) fractions in this setting of
elderly patients, mainly due to the shorter duration of the
course and in the view of more sustainable treatment
administration for these frail patients and in order to reduce
costs. 
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